Expanding on this trend, we believe that there is a need for designing clinical trials that will examine the effects of GH, targeting specific patient populations; indeed, major pathophysiologic differences exist not only between patients with dilated cardiomyopathy and coronary artery disease, but also among different stages of MI. Here, GH1 is linked to coronary artery disorder.